CDK versus GSK-3 inhibition: a purple haze no longer?
The ubiquitous ATP binding site offers a global target for protein kinase inhibitors. The corollary is that molecular selectivity with such agents may be difficult to achieve and ascertain. A relevant example is discussed in terms of design and biomedical rationale.
Fischer
Peter M
PM
Cyclacel Limited, James Lindsay Place, Dundee, DD1 5JJ, Scotland.
D000255:Adenosine Triphosphate / Q000378:metabolism; D001665:Binding Sites; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D008958:Models, Molecular; D017434:Protein Structure, Tertiary; D013379:Substrate Specificity
D004791:Enzyme Inhibitors; D000255:Adenosine Triphosphate; D018844:Cyclin-Dependent Kinases; D038362:Glycogen Synthase Kinase 3